Pan-cancer Bioinformatics Analysis of the Double-edged Role of Hypoxia-inducible Factor 1α (HIF-1α) in Human Cancer.

Background/Aim Despite the emergence of cellular, animal, and clinical-based evidence demonstrating a link between hypoxia-inducible factor-1α (HIF-1α) and malignancy, the comprehensive assessment of HIF-1α in pan-cancer patients remains unclear, particularly regarding HIF-1α expression and its association with immune infiltration and immune checkpoint. The present study aimed to investigate the role of HIF-1α expression in various types of malignancies through bioinformatics analysis. Materials and Methods We investigated the expression and prognostic value of HIF-1α in pan-cancer based on the TCGA (The Cancer Genome Atlas) dataset. The abundance of immune infiltration was estimated by xCell immune deconvolution methods. We investigated the relationship of HIF-1α expression with immune infiltration and immune checkpoint gene expression, with a focus on gastric adenocarcinoma (STAD) and lung squamous cell carcinoma (LUSC). Results HIF-1α expression had different effects on the prognosis of various cancers. In contrast to the protective effect of HIF-1α expression in LUSC, high levels of HIF-1α expression played a detrimental role in the survival of STAD patients. There was a significant positive correlation between HIF-1α expression and immune infiltration in STAD patients, including regulatory T-cells (Tregs), T-cell CD4+ Th2, neutrophils, M1 and M2 macrophages. In addition, immune checkpoint molecules showed different HIF-1α-related profiles in various carcinomas. Conclusion A relatively comprehensive view of the oncogenic role of HIF-1α in various tumors based on a pan-cancer analysis is provided in this study. HIF-1α may be considered a poor prognostic biomarker for STAD and, moreover, it may be involved in regulating tumor immune infiltration.

• Publication year

  2022

• Venue

  Cancer Diagnosis & Prognosis

• Publication date

  2022-03-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.21873/cdp.10104PMID 35399173PMCID PMC8962818
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• T‐cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer

  2021cited by this paper
• Pancancer survival analysis of cancer hallmark genes

  2020cited by this paper
• Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors

  2020cited by this paper
• Activated HIF1α of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer

  2020cited by this paper
• HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.

  2019cited by this paper
• Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

  2019cited by this paper
• Macrophages and Metabolism in the Tumor Microenvironment.

  2019cited by this paper
• Role of hypoxia in cancer therapy by regulating the tumor microenvironment

  2019cited by this paper
• HIF-1α/Wnt signaling-dependent control of gene transcription regulates neuronal differentiation of glioblastoma stem cells

  2019cited by this paper
• Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.

  2019cited by this paper
• Siglec-15: An Attractive Immunotherapy Target.

  2019cited by this paper
• Mechanisms Controlling PD-L1 Expression in Cancer.

  2019cited by this paper
• Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma

  2019cited by this paper
• HIF-1α Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma

  2019cited by this paper
• Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment

  2018cited by this paper
• When worlds collide: Th17 and Treg cells in cancer and autoimmunity

  2018cited by this paper
• Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis.

  2018cited by this paper
• Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer

  2018cited by this paper
• ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis

  2018cited by this paper
• Tim‐3 and its role in regulating anti‐tumor immunity

  2017cited by this paper
• Follicular Helper T Cells.

  2016cited by this paper
• Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer.

  2016cited by this paper
• The angiogenic switch leads to a metabolic shift in human glioblastoma

  2016cited by this paper
• Hypoxia-Inducible Factors: Master Regulators of Cancer Progression.

  2016cited by this paper
• Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

  2016cited by this paper
• Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

  2015cited by this paper
• XBP 1 Promotes Triple Negative Breast Cancer By Controlling the HIF 1 α Pathway

  2014cited by this paper
• PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

  2014cited by this paper
• XBP1 Promotes Triple Negative Breast Cancer By Controlling the HIF1 α Pathway

  2014cited by this paper
• Treg functional stability and its responsiveness to the microenvironment

  2014cited by this paper
• Differential expression of hypoxia-inducible factor 1α in non-small cell lung cancer and small cell lung cancer

  2012cited by this paper
• Hypoxia-inducible factors and the response to hypoxic stress.

  2010cited by this paper
• HIF-1α determines the metastatic potential of gastric cancer cells

  2009cited by this paper
• Regulation of glucose metabolism-related genes and VEGF by HIF-1alpha and HIF-1beta, but not HIF-2alpha, in gastric cancer.

  2009cited by this paper
• Tumor hypoxia and malignant progression.

  2009cited by this paper
• High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF.

  2008cited by this paper
• Oxygen, Hypoxia, and Stress

  2007cited by this paper
• Over expression of hypoxia-inducible factor-1alpha in renal and bladder cancer cells increases tumorigenic potency.

  2005cited by this paper
• Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma.

  2004cited by this paper
• Targeting HIF-1 for cancer therapy

  2003cited by this paper
• HIF-1alpha is essential for myeloid cell-mediated inflammation.

  2003cited by this paper
• Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival

  2001cited by this paper
• Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.

  1999cited by this paper

• No citing papers are available for this paper.